Mankind Pharma Q4 FY26 Earnings Call: Guides Double-Digit Revenue Growth, Chronic Share Nears 40%

Mankind Pharma Ltd held its Q4 FY26 earnings call on May 19, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials & Operating Metrics

• Q4 FY26 total revenue— Rs.3,443 Cr, up 11.8% YoY, led by 13.4% domestic growth; full-year FY26 revenue rose 17% YoY to Rs.14,278 Cr (vs. Rs.12,207 Cr in FY25).
• Q4 FY26 adjusted EBITDA margin— expanded 400 bps YoY to 27.1% (reported 26.4%, difference from labour code adoption); full-year FY26 adjusted EBITDA was 25.4%, within the 25–26% guidance range.
• Q4 FY26 PAT— Rs.559 Cr, +30.4% YoY, with PAT margin improving 230 bps to 16.2%; FY26 PAT declined 3.4% to Rs.1,938 Cr (margin 13.6%) due to higher finance cost, depreciation, and lower other income from the BSB acquisition.
• FY26 diluted EPS— Rs.46.3; cash EPS at Rs.68.1; volume growth improved to 2.3% in FY26 (vs. 0.5% in FY25), with PCPM rising to Rs.7.2 lakh/month (from Rs.6.5 lakh).
• Net working capital— 52 days as of 31 March 2026 (vs. 50 in FY25); CFO-to-EBITDA ratio improved to 89% (from 80% in FY25).
• Net debt— Rs.3,932 Cr as of 31 March 2026; net debt-to-adjusted EBITDA of 1.1× in Q4 FY26, with management reiterating on-track debt repayment by FY28.

Chronic Share Nears 40% as Acute Portfolio Recovers

• Chronic therapy contribution— reached ~39% for full FY26 and ~40% in Q4 FY26 (+190 bps YoY for the full year); chronic portfolio grew 1.1× IPM in FY26 but0.9× in Q4 FY26, which management views as "short-term noise".
• Anti-diabetes (ex-GLP-1)— outperformed IPM by 1.6× in FY26 with 5% volume growth, improving CVM rank to #4; cardiac therapies grew 14.7% in Q4 FY26 per IQVIA.
• Acute therapy growth— muted in FY26 but showed sequential improvement from Q2 through Q4 FY26; management expects acute to match IPM growth in FY26-27.
• Vona-Prozon— now the #1 prescribed brand by value and volume in its category; gynecology grew 10.8% YoY with IVF brands Folicraft (+52%) and HMG (+40%).
• Telmikind— surpassed Rs.750 Cr in annual revenue; the count of Rs.200 Cr+ brands grew to 13 (from 11 in FY25) and Rs.50 Cr+ brands to 54 (from 49).
• Prescription leadership— maintained for the 9th consecutive year: rank #1 with 15.1% prescription share and 84.1% prescriber penetration.

Measured GLP-1 Entry with Long-Term Value Focus

• GLP-1 pen launch— Mankind launched its GLP-1 product approximately one month ago (Q1 FY26-27), targeting endocrinologists; management is prioritising long-term value creation over near-term market share, with "no rush to launch vials or cut prices".
• Adjacent therapy investment— underway in vitamins, minerals, and protein products to complement the GLP-1 franchise in what management described as a "crowded market".
• GLP-1 impact on core therapies— management stated it is "too early" to see a direct impact on primary anti-diabetic and cardiac therapies; customer feedback suggests no significant impact yet.
• Clonazepam brand acquisition— acquired from Roche during Q4 FY26 to strengthen the neuropsychiatry portfolio; OTC business grew 20% in Q4 FY26 to Rs.213 Cr, with modern trade & e-commerce up 57% YoY.
• Biotech facility investment— board approved up to Rs.500 Cr in subsidiary Mankind Medicare for a best-in-class biotech facility in Vadodara; capex to be incurred in FY27-28.

BSV Integration Deepens, International Business Scales

• BSV anti-D brand— holds 100% market share in India, with sales exceeding Rs.200 Cr in FY26; state coverage expanded from 12 to 15+ states over two years by FY26, with two hospitals added in Tamil Nadu and Uttar Pradesh in FY25.
• Untapped addressable market— penetration among at-risk women is only 5% as of FY26; management guided mid-teens growth continuing into FY27, supported by awareness campaigns featuring Amitabh Bachchan.
• BSV International business— expected to grow at high teens to 20% in FY26-27, driven by women's healthcare & IVF products in semi-regulated markets (Philippines, Malaysia, Africa).
• Domestic BSV initiatives— gyne coverage increased from 32,000+ to 37,000+ doctors; 90% of IVF centers covered; key product Polygraph growing >40%.
• BSP acquisition integration— Rajeev Juneja reiterated that the 18–19-month-old acquisition is "fully streamlined" in domestic and international operations, with the R&D platform expected to deliver products "over the next 3 to 5 years".
• International business— Q4 export revenue grew 4% YoY to Rs.557 Cr (impacted by geopolitical headwinds); FY26 full-year exports rose 35% YoY to Rs.2,061 Cr; Udaipur and Ambernath facilities received EU-GMP certification.

Margin Guidance Tightens, Deleveraging on Track

• EBITDA margin guidance FY26-27— 25.5%–26.5% (target of 26.5%), better than FY26's 25.4%,caveated by geopolitical and market conditions; Q4 FY26 margin of ~27% was the strongest in recent quarters.
• Employee cost— flat at 22.1% of revenue in FY26 vs. FY25; absolute increase of Rs.491 Cr partly due to BSV full-year inclusion; normalized YoY increase ~10%; long-term target of ~22% of sales.
• Other expenses (SG&A + R&D)— FY26 at Rs.3,424 Cr (24% of sales); normalized FY25 was 23.6% ex-Rs.130 Cr one-offs; R&D spend at 2.8% of sales for FY26 (vs. 2.2% in FY25), within the 2.5–3% guidance range.
• Debt repayment schedule— Rs.1,250 Cr repaid in April FY26-27; another Rs.1,250 Cr due in October FY26-27; Rs.2,500 Cr to be repaid in FY27-28; net debt-to-adjusted EBITDA guided at 0.5× for FY26-27.
• CAPEX— FY26 at Rs.737 Cr (5.2% of revenue); FY27 CAPEX guided at 6–7% of FY27 revenue, primarily for the Vadodara biotech facility.
• Effective tax rate— guided at 25–26% for FY26-27 (up from 15–16% in FY26) as the section exemption ended.

Double-Digit Growth Ambition for FY26-27

• Revenue growth guidance FY26-27— management expects at least double-digit top-line growth, outperforming IPM, driven by normalising acute portfolio, sustained chronic momentum, and specialty/GLP-1 opportunities.
• EBITDA margin guidance FY26-27— 25.5%–26.5% (Rajeev Juneja: "better than FY25-26"), with a target of 26.5%subject to geopolitical and market conditions.
• Price hike & channel mix— FY26 price hike of 4.2% in line with the industry average of 4.4% per IQVIA; modern trade & e-com channel share rose to 13% in FY26 (from 9% in FY25), with medium-term normalised growth expectation of high teens.
• Consumer health— targets double-digit growth in FY27-28, driven by brand extensions and e-commerce growing 50%+; no new near-term product launches, focus on scaling existing FY25-26 brands.
• Supply chain headwinds— management acknowledged raw material, packaging, and excipient disruption due to the Middle East war (period unspecified); precautions taken but outcome uncertain.
• Export growth expectations— management expects high double-digit growth in FY27-28 for both international business units, with VSB recovering followingLatin America, CIS, and Philippines leadership changes.